VIVUS (STU:VIU1) Debt-to-Equity : -3.27 (As of Mar. 2020)

View and export this data going back to . Start your Free Trial

What is VIVUS Debt-to-Equity?

VIVUS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2020 was €165.22 Mil. VIVUS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2020 was €53.68 Mil. VIVUS's Total Stockholders Equity for the quarter that ended in Mar. 2020 was €-66.93 Mil. VIVUS's debt to equity for the quarter that ended in Mar. 2020 was -3.27.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for VIVUS's Debt-to-Equity or its related term are showing as below:

STU:VIU1's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

VIVUS Debt-to-Equity Historical Data

The historical data trend for VIVUS's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIVUS Debt-to-Equity Chart

VIVUS Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Debt-to-Equity

Get a 7-Day Free Trial

-32.66

13.27

-25.24

-7.36

-3.51

VIVUS Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Debt-to-Equity	Get a 7-Day Free Trial															-6.25	-5.60	-3.86	-3.51	-3.27

Competitive Comparison of VIVUS's Debt-to-Equity

For the Biotechnology subindustry, VIVUS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VIVUS's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VIVUS's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where VIVUS's Debt-to-Equity falls into.

VIVUS Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

VIVUS's Debt to Equity Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(165.396	+	53.391)	/	-62.302
	=	-3.51

VIVUS's Debt to Equity Ratio for the quarter that ended in Mar. 2020 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(165.22	+	53.675)	/	-66.93
	=	-3.27

VIVUS (STU:VIU1) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

VIVUS Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of VIVUS's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

VIVUS (STU:VIU1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIVUS Inc (STU:VIU1) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 East Hamilton Avenue, Suite 550, Campbell, CA, USA, 95008

Website

http://www.vivus.com

VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and STENDRA/SPEDRA, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

VIVUS (STU:VIU1) Headlines

No Headlines